Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors

View ORCID ProfileA Coosemans, View ORCID ProfileJ Ceusters, C Landolfo, T Baert, W Froyman, R Heremans, G Thirion, S Claes, J Oosterlynck, R Wouters, A Vankerckhoven, F Moro, F Mascilini, A Neumann, AS Van Rompuy, D Schols, J Billen, T Van Gorp, I Vergote, T Bourne, C Van Holsbeke, V Chiappa, G Scambia, A Testa, D Fischerova, D Timmerman, View ORCID ProfileB Van Calster
doi: https://doi.org/10.1101/2024.03.14.24304282
A Coosemans
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A Coosemans
  • For correspondence: an.coosemans{at}kuleuven.be
J Ceusters
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J Ceusters
C Landolfo
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
3Queen Charlotte’s and Chelsea Hospital, Imperial College, London, UK
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T Baert
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
6Department of Oncology, Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W Froyman
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Heremans
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Thirion
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Claes
7Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy (Rega Institute), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Oosterlynck
8Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Wouters
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
9Oncoinvent AS, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Vankerckhoven
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Moro
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Mascilini
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Neumann
10Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AS Van Rompuy
11Department of Pathology, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Schols
7Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy (Rega Institute), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Billen
8Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T Van Gorp
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
6Department of Oncology, Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I Vergote
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
6Department of Oncology, Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T Bourne
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
3Queen Charlotte’s and Chelsea Hospital, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Van Holsbeke
12Department of Obstetrics and Gynecology, Ziekenhuis Oost-Limburg, Genk, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V Chiappa
13Department of Gynecologic Oncology, National Cancer Institute of Milan, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Scambia
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Testa
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Fischerova
10Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Timmerman
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B Van Calster
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
14Department of Biomedical Data Sciences, Leiden University Medical Centre (LUMC), Leiden, Netherlands
15Leuven Unit for Health Technology Assessment Research (LUHTAR), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for B Van Calster
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The ADNEX model (Assessment of Different NEoplasias in the adnexa) is the best performing model to predict the risk of malignancy (binary) and type of malignancy (multiclass) in ovarian tumors. The immune system plays a role in the onset and progression of ovarian cancer. Preliminary research has suggested that immune-related biomarkers can help in the discrimination of ovarian tumors. We aimed to assess which proteins have the most additional diagnostic value in addition to ADNEX’ clinical and ultrasound predictors.

Materials and methods In this exploratory diagnostic study, 1086 patients with an adnexal mass scheduled for surgery were consecutively enrolled at five oncology centers and one non- oncology center in Belgium, Italy, Czech Republic and United Kingdom between 2015 and 2019. The quantification of 33 serum proteins was carried out preoperatively, using multiplex high throughput immunoassays (Luminex) and electrochemiluminescence immuno-assay (ECLIA). Logistic regression analysis was performed for ADNEX’ clinical and ultrasound predictors alone (age, maximum diameter of lesion, proportion of solid tissue, presence of >10 cyst locules, number of papillary projections, acoustic shadows and ascites) and after adding proteins. We reported the AUC for benign vs malignant, Polytomous Discrimination Index (PDI; a multiclass AUC) and pairwise AUCs for pairs of tumor types. AUCs were corrected for optimism using bootstrapping.

Results After applying exclusion criteria, 932/1086 patients were eligible for analysis (474 benign, 135 borderline, 84 stage I primary invasive cancer, 208 stage II-IV primary invasive cancer, 31 secondary metastatic invasive tumors). ADNEX predictors alone had an AUC of 0.909 (95% CI 0.894-0.929) to discriminate benign from malignant tumors, and a PDI of 0.532 (0.510-0.589). HE4 yielded the highest increase in AUC (+0.026), followed by CA125 (+0.017). CA125 yielded the highest increase in PDI (+0.049), followed by HE4 (+0.036). Whereas CA125 mainly improved pairwise AUCs between different types of invasive tumors (increases between 0.020-0.165 over ADNEX alone), HE4 mainly improved pairwise AUCs for benign tumors versus stage I (+0.022) and benign tumors versus stage II-IV ovarian cancers (+0.028). CA72.4 might be useful to distinguishing secondary metastatic tumors from benign, borderline, and stage I tumors. CA15.3 might be useful to discriminate borderline tumors from stage I and stage II-IV tumors. Distinguishing stage I and borderline tumors (AUCs ≤ 0.72) and stage I and secondary metastatic tumors (AUCs ≤ 0.76) remained difficult after adding proteins.

Conclusions CA125 had the highest added value over clinical and ultrasound predictors to distinguish between the five tumor types, followed by HE4. In addition, CA72.4 and CA15.3 may further improve discrimination but findings for these proteins should be confirmed. The immune-related proteins were in general not able to discriminate the groups.

Competing Interest Statement

TBo reports grants, personal fees, and travel support from Samsung Medison; travel support from Roche Diagnostics; and personal fees from GE Healthcare; all outside the submitted work. RW is employed by Oncoinvent AS. AC is a contracted researcher for Oncoinvent AS and Novocure and a consultant for Sotio a.s., Epics Therapeutics SA and Molecular Partners. BVC and DT report consultancy work done by KU Leuven to help implementing and testing the ADNEX model in ultrasound machines by Samsung Medison and GE Healthcare, outside the submitted work. Tba reports grants, personal fees, and travel support from Roche, Novartis, GSK, MSD, and AstraZeneca, all outside the submitted work. All other authors declare no competing interests.

Funding Statement

This research was funded by Kom Op Tegen Kanker (Stand up to Cancer), the Flemish cancer society (2016/10728/2603). The IOTA5 study is supported by the Research Foundation-Flanders (FWO) (projects G049312N, G0B4716N, 12F3114N, G097322N), and Internal Funds KU Leuven (projects C24/15/037 and C24M/20/064). DT is senior clinical investigator of FWO. TVG is a Senior Clinical Investigator of FWO (18B2921N). TBo is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare UK National Health Service (NHS) Trust and Imperial College London. CL is supported by Linbury Trust Grant LIN 2600. ECLIA reagent were a kind gift from Roche Diagnostics.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of University Hospitals Leuven gave ethical approval for this work, as central Ethics Committee. Ethics committees of Università Cattolica del Sacro Cuore (Rome, Italy), General Faculty Hospital of the Charles University (Prague, Czech Republic), Queen Charlotte's and Chelsea Hospital (London, UK), Ziekenhuis Oost-Limburg (Genk, Belgium), and Istituto Nazionale dei Tumore (Milan, Italy) gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

The pseudonymized data and data dictionary is stored in the KU Leuven Research Data Repository (RDR), https://doi.org/10.48804/TXL95Z. The dataset is not publicly available because this was not part of the informed consent. However, the dataset may be obtained following permission of prof. AC (an.coosemans{at}kuleuven.be) and prof. DT (dirk.timmerman{at}uzleuven.be) and after fulfilling all data transfer requirements.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted March 15, 2024.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
A Coosemans, J Ceusters, C Landolfo, T Baert, W Froyman, R Heremans, G Thirion, S Claes, J Oosterlynck, R Wouters, A Vankerckhoven, F Moro, F Mascilini, A Neumann, AS Van Rompuy, D Schols, J Billen, T Van Gorp, I Vergote, T Bourne, C Van Holsbeke, V Chiappa, G Scambia, A Testa, D Fischerova, D Timmerman, B Van Calster
medRxiv 2024.03.14.24304282; doi: https://doi.org/10.1101/2024.03.14.24304282
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
A Coosemans, J Ceusters, C Landolfo, T Baert, W Froyman, R Heremans, G Thirion, S Claes, J Oosterlynck, R Wouters, A Vankerckhoven, F Moro, F Mascilini, A Neumann, AS Van Rompuy, D Schols, J Billen, T Van Gorp, I Vergote, T Bourne, C Van Holsbeke, V Chiappa, G Scambia, A Testa, D Fischerova, D Timmerman, B Van Calster
medRxiv 2024.03.14.24304282; doi: https://doi.org/10.1101/2024.03.14.24304282

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Obstetrics and Gynecology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)